The risk of AD is up to 10–60 fold higher in APOE-ε4 homozygous carriers, but the ε4 allele can not identify the onset of AD or predict the rate at which MCI progresses to AD (Farrer et al., 1997). This evidence concerns the gene APOE and Alzheimer disease.